论文部分内容阅读
采用随机、开放、NPH重组人胰岛素平行对照方法,将70例口服降糖药治疗效果欠佳的2型糖尿病患者随机分入甘精胰岛素组(n=35)和NPH重组人胰岛素组(n=35),观察二组低血糖的发生率。结果甘精胰岛素组低血糖的发生率比NPH重组人胰岛素组少的多(甘精胰岛素组发生低血糖3例,发生率8.6%;NPH重组人胰岛素组发生低血糖11例,发生率31.4%,χ2=5.72,P<0.05)。结论甘精胰岛素的应用能减少低血糖事件的发生,使患者依从性提高,有利于血糖的控制。
A randomized, open, NPH recombinant human insulin parallel control method was used to randomize 70 patients with type 2 diabetes who were not well treated with oral hypoglycemic agents into insulin glargine group (n = 35) and NPH recombinant human insulin group (n = 35), observed the incidence of hypoglycemia in two groups. Results The incidence of hypoglycemia in the insulin glargine group was much less than that in the NPH recombinant human insulin group (3 cases occurred in the insulin glargine group, the incidence was 8.6%; in the NPH recombinant human insulin group, 11 cases occurred hypoglycemia, the incidence rate was 31.4% , χ2 = 5.72, P <0.05). Conclusion The application of insulin glargine can reduce the incidence of hypoglycemic events, improve patient compliance, is conducive to the control of blood glucose.